Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Mouse ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13) ELISA kit

Mouse ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13) ELISA kit

  • 中文名稱：
    小鼠ADAM金屬肽酶含血小板反應(yīng)蛋白1型13(ADAMTS13)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-EL001301MO
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    This Mouse ADAMTS13 ELISA Kit was designed for the quantitative measurement of Mouse ADAMTS13 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 78 pg/mL-5000 pg/mL and the sensitivity is 19.5 pg/mL.

  • 別名：
    Adamts13 ELISA kit; Gm710A disintegrin and metalloproteinase with thrombospondin motifs 13 ELISA kit; ADAM-TS 13 ELISA kit; ADAM-TS13 ELISA kit; ADAMTS-13 ELISA kit; EC 3.4.24.87 ELISA kit; von Willebrand factor-cleaving protease ELISA kit; vWF-CP ELISA kit; vWF-cleaving protease ELISA kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Mus musculus (Mouse)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    78 pg/mL-5000 pg/mL
  • 靈敏度：
    19.5 pg/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cancer
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of mouse ADAMTS13 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    SampleSerum(n=4)
    1:1000Average %95
    Range %89-98
    1:2000Average %92
    Range %88-95
    1:4000Average %92
    Range %85-95
    1:8000Average %98
    Range %92-101
  • 回收率：
    The recovery of mouse ADAMTS13 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9186-94
    EDTA plasma (n=4)10398-107
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    50002.401 2.476 2.439 2.337
    25001.884 1.875 1.880 1.778
    12501.413 1.424 1.419 1.317
    6250.777 0.798 0.788 0.686
    3120.466 0.476 0.471 0.369
    1560.265 0.258 0.262 0.160
    780.176 0.184 0.180 0.078
    00.101 0.103 0.102
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點(diǎn)詳情

  • 功能：
    Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation.
  • 基因功能參考文獻(xiàn)：
    1. ADAMTS13-vWF axis is partially involved in the pathophysiology of kidney ischemic reperfusion injury. PMID: 27507004
    2. Adamts13 deficiency in obese mice promotes hepatic microthrombosis. PMID: 27604194
    3. results suggest that ADAMTS13 controls key steps of ischemic vascular remodeling and that recombinant ADAMTS13 is a putative therapeutic avenue for promoting stroke recovery. PMID: 28428179
    4. ADAMTS13 retards progression of diabetic nephropathy, most likely by inhibiting VWF-dependent intrarenal thrombosis. PMID: 28495930
    5. administration of ADAMTS13 5 minutes after occlusion dose-dependently dissolved these t-PA-resistant thrombi resulting in fast restoration of MCA patency and consequently reduced cerebral infarct sizes PMID: 26929275
    6. Sleeping beauty transposon-mediated gene therapy achieved sustained expression of transgene ADAMTS13 and long-term prophylaxis against congenital thrombotic thrombocytopenic purpura in Adamts13(-/-) mice. PMID: 28254814
    7. Results also suggest that Toxoplasma gondii-mediated apoptosis might play a pivotal role and a different type of role in the mechanism of neurodegeneration and neuropathology in the process of toxoplasma encephalitis. Furthermore, expression of ADAMTS-13 might give an idea of the progress and is critical for diagnosis of this disease. PMID: 26542631
    8. Letter: deficiency of ADAMTS13 results in increased formation of venous thrombosis in mice. PMID: 25855507
    9. ADAMTS13 substrate specificity PMID: 25849793
    10. Data indicate that the p.D187H mutation impairs ADAMTS13 activity and secretion and may contribute to thrombotic thrombocytopenic purpura. PMID: 25442981
    11. Data show that metalloendopeptidase ADAMTS13 does not directly promote development of adipose tissue. PMID: 25813552
    12. findings provide further evidence on the pathophysiological role for the ADAMTS13/VWF axis in atherosclerosis PMID: 24261607
    13. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner. PMID: 24357063
    14. Three novel mutations in a homozygous state were identified in these patients: c.1308G>C, c.428T>C (p.Ile143Thr) and c.1709A>G (p.Tyr570Cys) PMID: 24115559
    15. The results indicate that the microvascular process induced by ADAMTS13 deficiency triggers complement activation on platelets and the endothelium, which may contribute to formation of thrombotic microangiopathy. PMID: 23878316
    16. model of acute myocardial infarction in ADAMTS13 gene deleted (Adamts13 -/-) mice PMID: 23051932
    17. We hypothesize that ADAMTS13 protects brain from ischemia-reperfusion injury by regulating von Willebrand factor -dependent inflammation as well as microvascular plugging PMID: 22212812
    18. Cyclophilin B activity regulated secretion and activity of ADAMTS13. PMID: 23144461
    19. Adamts13(-/-) mice developed larger myocardial infarctions than wild-type control mice. PMID: 22915644
    20. ADAMTS13 and VWF are causally involved in myocardial ischemia/reperfusion injury. PMID: 22983446
    21. We revealed the epitopes of 11 monoclonal anti-ADAMTS13 antibodies on each of the domains and clarified their association with inhibitory effects on VWF catalysis under static conditions. PMID: 22721582
    22. Provide new evidence for ADAMTS13 in reducing VWF-mediated acute cerebral inflammation following ischemic stroke. PMID: 22712744
    23. ADAMTS13 plays a critical role in modulating the development of early atherosclerosis. PMID: 22652598
    24. Prophylactic administration of 200 units/kg recombinant human ADAMTS13 protected ADAMTS13 knockout mice from developing thrombotic thrombocytopenic purpura. PMID: 22529289
    25. Gender-dependent up-regulation of ADAMTS-13 in mice with obesity and hypercholesterolemia. PMID: 22192156
    26. Findings suggest a new functional role for the antithrombotic enzyme ADAMTS13 in reducing excessive vascular inflammation and plaque formation during early atherosclerosis. PMID: 22123843
    27. Results suggest that the amino terminus of ADAMTS13, specifically the variable region of the spacer domain, is crucial for modulation of arterial thromboses under (patho)physiological conditions. PMID: 21799176
    28. Glomerular endothelial cells express and secrete ADAMTS13. PMID: 21720563
    29. in vivo imaging analysis revealed that ADAMTS13 regulates the disappearance of platelet strings on DDAVP-stimulated VECs and on the FeCl3-injured venous vascular wall through the cleavage of UL-VWF. PMID: 21494805
    30. ADAMTS13 CUB and T2-8 domains influence proteolysis of platelet-decorated VWF strings in vivo PMID: 20695979
    31. von Willebrand factor clearance does not involve proteolysis by ADAMTS-13 PMID: 20704649
    32. Shiga toxin B subunits induce thrombotic microangiopathy in Adamts13(-/-) mice. PMID: 20644116
    33. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. PMID: 20200350
    34. ADAMTS13 down-regulates platelet adhesion and aggregation in vivo, and ADAMTS13 deficiency can provide enhanced thrombus formation at the site of vascular lesions in mice PMID: 20047094
    35. ADAMTS13 may protect the brain from ischemia by regulating VWF-platelet interactions after reperfusion. PMID: 19965676
    36. analysis of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease PMID: 15136581
    37. Identification of the liver cell-type expressing ADAMTS13 will have is important for understanding pathophysiological mechanisms regulating ADAMTS13 expression. PMID: 15806136
    38. characterization of the full-length murine ADAMTS13 PMID: 15869605
    39. REVIEW: the nature of ADAMTS13's interaction with von Willebrand factor and the pathogenesis of clinical thrombotic thrombocytopenic purpura, especially in relation to ADAMTS13 PMID: 17414218
    40. REVIEW: Accumulated clinical information on patients with ADAMTS13 deficiency and mice lacking the Adamts13 gene indicates that additional environmental or genetic susceptibility factors are required to trigger thrombotic thrombocytopenic purpura. PMID: 17414219
    41. the plasma ADAMTS13 activity levels of mouse strains segregated into a high and a low group. Low ADAMTS13 activity was detected in mice containing 2 alleles of intracisternal A-type particle (IAP) retrotransposon sequence PMID: 17426255
    42. Imbalance between the blood von Willebrand factor and ADAMTS13 levels may occur in endotoxinemia, which may partly contribute to the thrombotic state associated with endotoxinemia. PMID: 18006046
    43. the potential roles played by ADAMTS13 and VWF in TTP, endotoxemia, and normal hemostasis. PMID: 18083848
    44. a new mechanism of anthrax coagulopathy affecting the levels and functional activities of both VWF and its natural regulator ADAMTS13. This mechanism may contribute to hemorrhage and thrombosis typical in anthrax. PMID: 18263586
    45. ADAMTS13 has an important role in preventing excessive spontaneous Weibel-Palade body secretion, and in the regulation of leukocyte adhesion and extravasation during inflammation PMID: 18695007
    46. the C-terminally truncated ADAMTS13 exhibited decreased activity in the cleavage of VWF under high shear rate and accelerated thrombogenesis PMID: 19109562
    47. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. PMID: 19687510

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 組織特異性：
    Plasma. Expression is consistently high in liver, medium in lung and spleen, low in skeletal muscle and undetectable in heart, brain, kidney and testis.
  • 數(shù)據(jù)庫鏈接：